S&P 500   4,221.02
DOW   33,061.57
QQQ   352.01
Is This The Collapse of Icahn Enterprises ?
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
20 Best Healthcare Dividend Stocks to Invest in
Money stored in Venmo and other payment apps could be vulnerable, financial watchdog warns
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
Nordstrom's Earnings Beat, A Rally In The Making
Elliott Management Says Goodyear Tire Worth At Least $21 a Share
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
What Does the Airbnb Guidance Drop Say About Travel Demand?
What is the Penalty for Excess Contributions to an IRA?
S&P 500   4,221.02
DOW   33,061.57
QQQ   352.01
Is This The Collapse of Icahn Enterprises ?
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
20 Best Healthcare Dividend Stocks to Invest in
Money stored in Venmo and other payment apps could be vulnerable, financial watchdog warns
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
Nordstrom's Earnings Beat, A Rally In The Making
Elliott Management Says Goodyear Tire Worth At Least $21 a Share
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
What Does the Airbnb Guidance Drop Say About Travel Demand?
What is the Penalty for Excess Contributions to an IRA?
S&P 500   4,221.02
DOW   33,061.57
QQQ   352.01
Is This The Collapse of Icahn Enterprises ?
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
20 Best Healthcare Dividend Stocks to Invest in
Money stored in Venmo and other payment apps could be vulnerable, financial watchdog warns
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
Nordstrom's Earnings Beat, A Rally In The Making
Elliott Management Says Goodyear Tire Worth At Least $21 a Share
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
What Does the Airbnb Guidance Drop Say About Travel Demand?
What is the Penalty for Excess Contributions to an IRA?
S&P 500   4,221.02
DOW   33,061.57
QQQ   352.01
Is This The Collapse of Icahn Enterprises ?
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
20 Best Healthcare Dividend Stocks to Invest in
Money stored in Venmo and other payment apps could be vulnerable, financial watchdog warns
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
Nordstrom's Earnings Beat, A Rally In The Making
Elliott Management Says Goodyear Tire Worth At Least $21 a Share
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
What Does the Airbnb Guidance Drop Say About Travel Demand?
What is the Penalty for Excess Contributions to an IRA?
Top-Rated StocksTop-Rated
NASDAQ:ITCI

Intra-Cellular Therapies (ITCI) Stock Forecast, Price & News

$59.53
+0.15 (+0.25%)
(As of 06/1/2023 ET)
Compare
Today's Range
$58.38
▼
$60.46
50-Day Range
$46.73
▼
$66.44
52-Week Range
$42.01
▼
$66.56
Volume
551,070 shs
Average Volume
644,930 shs
Market Capitalization
$5.71 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$74.45
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability

Intra-Cellular Therapies MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.90 Rating Score
Upside/​Downside
25.1% Upside
$74.45 Price Target
Short Interest
Bearish
3.71% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.23
Upright™ Environmental Score
News Sentiment
0.54mentions of Intra-Cellular Therapies in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$5.83 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.32) to ($1.12) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.56 out of 5 stars

Medical Sector

257th out of 1,980 stocks

Pharmaceutical Preparations Industry

93rd out of 978 stocks

See Top Rated MarketRank™ Stocks Here

ITCI stock logo

About Intra-Cellular Therapies (NASDAQ:ITCI) Stock

Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company. It focuses on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. The firm's lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. It also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates in 2002 and is headquartered in New York, NY.

Receive ITCI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intra-Cellular Therapies and its competitors with MarketBeat's FREE daily newsletter.

ITCI Stock News Headlines

May 31, 2023 | finance.yahoo.com
Intra-Cellular Therapies Announces CAPLYTA Data Presentations at the American Society of Clinical Psychopharmacology Annual Meeting
May 31, 2023 | finance.yahoo.com
Intra-Cellular Therapies Announces CAPLYTA Data Presentations at the American Society of Clinical Psychopharmacology Annual Meeting
June 2, 2023 | Edge On The Street (Ad)
The Graphite Shortage Story You're Not Being Told
Graphite demand for EV batteries is expected to increase 10X from 2020 to 2030. And today, with NO graphite-producing mines in N. America, China has a stranglehold on our graphite supply. That's why the U.S. government is spending billions of dollars to ensure an adequate domestic supply of this metal that's vital for energy independence and national security.
May 28, 2023 | americanbankingnews.com
Brokerages Set Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Target Price at $74.45
May 17, 2023 | americanbankingnews.com
Head to Head Analysis: Intra-Cellular Therapies (NASDAQ:ITCI) and Arbutus Biopharma (NASDAQ:ABUS)
May 8, 2023 | msn.com
Mizuho Maintains Intra-Cellular Therapies (ITCI) Buy Recommendation
May 8, 2023 | finance.yahoo.com
Investing in Intra-Cellular Therapies (NASDAQ:ITCI) three years ago would have delivered you a 208% gain
May 8, 2023 | americanbankingnews.com
Intra-Cellular Therapies (NASDAQ:ITCI) Price Target Raised to $76.00
June 2, 2023 | Edge On The Street (Ad)
The Graphite Shortage Story You're Not Being Told
Graphite demand for EV batteries is expected to increase 10X from 2020 to 2030. And today, with NO graphite-producing mines in N. America, China has a stranglehold on our graphite supply. That's why the U.S. government is spending billions of dollars to ensure an adequate domestic supply of this metal that's vital for energy independence and national security.
May 8, 2023 | americanbankingnews.com
Cantor Fitzgerald Raises Intra-Cellular Therapies (NASDAQ:ITCI) Price Target to $90.00
May 5, 2023 | msn.com
Cantor Fitzgerald Maintains Intra-Cellular Therapies (ITCI) Overweight Recommendation
May 5, 2023 | msn.com
RBC Capital Maintains Intra-Cellular Therapies (ITCI) Outperform Recommendation
May 4, 2023 | finance.yahoo.com
‘Don’t let the earnings beats fool you’: Morgan Stanley advises investors to temper their optimism amidst a looming recession — use these 2 stocks for protection
May 4, 2023 | finanznachrichten.de
Intra-Cellular Therapies Inc.: Intra-Cellular Therapies Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 4, 2023 | msn.com
Recap: Intra-Cellular Therapies Q1 Earnings
May 4, 2023 | msn.com
Intra-Cellular Therapies Q1 2023 Earnings Preview
May 4, 2023 | finance.yahoo.com
Intra-Cellular Therapies Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 3, 2023 | americanbankingnews.com
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Receives $74.00 Average Price Target from Analysts
April 26, 2023 | finance.yahoo.com
Intra-Cellular Therapies to Host First Quarter 2023 Financial Results Conference Call and Webcast
April 25, 2023 | americanbankingnews.com
SVB Leerink Comments on Intra-Cellular Therapies, Inc.'s FY2027 Earnings (NASDAQ:ITCI)
April 22, 2023 | americanbankingnews.com
Morgan Stanley Begins Coverage on Intra-Cellular Therapies (NASDAQ:ITCI)
April 22, 2023 | americanbankingnews.com
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Director Sells $630,000.00 in Stock
April 21, 2023 | msn.com
Morgan Stanley Reiterates Intra-Cellular Therapies (ITCI) Overweight Recommendation
April 20, 2023 | msn.com
Morgan Stanley starts Intra-Cellular at Overweight on schizophrenia therapy
April 20, 2023 | msn.com
Morgan Stanley Initiates Coverage of Intra-Cellular Therapies (ITCI) with Overweight Recommendation
April 20, 2023 | finance.yahoo.com
IBD 50 Stocks To Watch: This Drug Stock Up 36% In Six Weeks After Positive Trial News
April 20, 2023 | americanbankingnews.com
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Short Interest Update
See More Headlines

ITCI Price History

ITCI Company Calendar

Last Earnings
5/04/2023
Today
6/02/2023
Next Earnings (Estimated)
8/08/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ITCI
CUSIP
N/A
CIK
1567514
Web
www.intracellulartherapies.com
Phone
(464) 440-9333
Fax
646-440-9334
Employees
512
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$74.45
High Stock Price Forecast
$98.00
Low Stock Price Forecast
$49.00
Forecasted Upside/Downside
+25.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.90
Research Coverage
10 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($2.40)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-256,260,000.00
Net Margins
-73.46%
Pretax Margin
-73.46%
Return on Equity
-33.92%
Return on Assets
-29.72%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
8.87
Quick Ratio
8.52

Sales & Book Value

Annual Sales
$250.31 million
Price / Sales
22.81
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$6.54 per share
Price / Book
9.10

Miscellaneous

Outstanding Shares
95,930,000
Free Float
92,377,000
Market Cap
$5.71 billion
Optionable
Optionable
Beta
1.15

Key Executives

  • Sharon MatesSharon Mates
    Chairman, President & Chief Executive Officer
  • Lawrence J. Hineline
    Chief Financial Officer, Treasurer & SVP-Finance
  • Robert E. Davis
    Chief Scientific Officer & Senior Vice President
  • Suresh DurgamSuresh Durgam
    Chief Medical Officer & Senior Vice President
  • Karen Patruno Sheehy
    Chief Compliance Officer & Senior Vice President

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













ITCI Stock - Frequently Asked Questions

Should I buy or sell Intra-Cellular Therapies stock right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Intra-Cellular Therapies in the last twelve months. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ITCI shares.
View ITCI analyst ratings or view top-rated stocks.

What is Intra-Cellular Therapies' stock price forecast for 2023?

10 analysts have issued 1-year target prices for Intra-Cellular Therapies' stock. Their ITCI share price forecasts range from $49.00 to $98.00. On average, they expect the company's share price to reach $74.45 in the next twelve months. This suggests a possible upside of 25.1% from the stock's current price.
View analysts price targets for ITCI or view top-rated stocks among Wall Street analysts.

How have ITCI shares performed in 2023?

Intra-Cellular Therapies' stock was trading at $52.92 at the beginning of 2023. Since then, ITCI shares have increased by 12.5% and is now trading at $59.53.
View the best growth stocks for 2023 here.

Are investors shorting Intra-Cellular Therapies?

Intra-Cellular Therapies saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 3,560,000 shares, an increase of 21.9% from the April 30th total of 2,920,000 shares. Based on an average daily trading volume, of 893,600 shares, the short-interest ratio is presently 4.0 days.
View Intra-Cellular Therapies' Short Interest.

When is Intra-Cellular Therapies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our ITCI earnings forecast.

How were Intra-Cellular Therapies' earnings last quarter?

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) released its quarterly earnings results on Thursday, May, 4th. The biopharmaceutical company reported ($0.46) EPS for the quarter, beating the consensus estimate of ($0.63) by $0.17. The biopharmaceutical company earned $95.31 million during the quarter, compared to the consensus estimate of $92.14 million. Intra-Cellular Therapies had a negative net margin of 73.46% and a negative trailing twelve-month return on equity of 33.92%.

What ETFs hold Intra-Cellular Therapies' stock?

ETFs with the largest weight of Intra-Cellular Therapies (NASDAQ:ITCI) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), AdvisorShares Psychedelics ETF (PSIL), SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), Virtus LifeSci Biotech Products ETF (BBP), iShares U.S. Pharmaceuticals ETF (IHE), Innovator IBD Breakout Opportunities ETF (BOUT) and Principal Healthcare Innovators ETF (BTEC).

What other stocks do shareholders of Intra-Cellular Therapies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Intra-Cellular Therapies investors own include Sorrento Therapeutics (SRNE), Amarin (AMRN), Gilead Sciences (GILD), CRISPR Therapeutics (CRSP), Synergy Pharmaceuticals (SGYP), Myovant Sciences (MYOV), Novavax (NVAX), Pfizer (PFE), AbbVie (ABBV) and Clovis Oncology (CLVS).

What is Intra-Cellular Therapies' stock symbol?

Intra-Cellular Therapies trades on the NASDAQ under the ticker symbol "ITCI."

Who are Intra-Cellular Therapies' major shareholders?

Intra-Cellular Therapies' stock is owned by many different retail and institutional investors. Top institutional shareholders include FMR LLC (12.45%), BlackRock Inc. (7.58%), Wellington Management Group LLP (5.24%), Wasatch Advisors LP (4.67%), State Street Corp (2.11%) and JPMorgan Chase & Co. (1.91%). Insiders that own company stock include Christopher D Alafi, Christopher D Alafi, Joel S Marcus, Lawrence J Hineline, Lawrence J Hineline, Mark Neumann, Michael Halstead, Nostrand Robert L Van, Rory B Riggs, Sharon Mates and Suresh K Durgam.
View institutional ownership trends.

How do I buy shares of Intra-Cellular Therapies?

Shares of ITCI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Intra-Cellular Therapies' stock price today?

One share of ITCI stock can currently be purchased for approximately $59.53.

How much money does Intra-Cellular Therapies make?

Intra-Cellular Therapies (NASDAQ:ITCI) has a market capitalization of $5.71 billion and generates $250.31 million in revenue each year. The biopharmaceutical company earns $-256,260,000.00 in net income (profit) each year or ($2.40) on an earnings per share basis.

How many employees does Intra-Cellular Therapies have?

The company employs 512 workers across the globe.

How can I contact Intra-Cellular Therapies?

Intra-Cellular Therapies' mailing address is 430 EAST 29TH STREET, NEW YORK NY, 10016. The official website for the company is www.intracellulartherapies.com. The biopharmaceutical company can be reached via phone at (464) 440-9333, via email at ir@intracellulartherapies.com, or via fax at 646-440-9334.

This page (NASDAQ:ITCI) was last updated on 6/2/2023 by MarketBeat.com Staff

My Account -